Recent studies reveal promising outcomes for discontinuing TKI therapy in select patients with Philadelphia ...

FDA approves tafasitamab with lenalidomide and rituximab, offering a groundbreaking chemotherapy-free treatment for relapsed ...

Panelists discuss how to approach a 67-year-old man with advanced polycythemia vera who is resistant to hydroxyurea, ...

FDA updates CAR T-cell therapy labels for liso-cel and ide-cel, easing monitoring requirements and expanding access for ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Despite major advances, real-world data show diminishing survival outcomes and treatment-limiting toxicities in second line ...

A recent trial reveals that nivolumab combined with chemotherapy significantly improves survival rates in older patients with ...

Surbhi Sidana, MD, discusses updates from the CARTITUDE-4 study assessing the CAR T therapy cilta-cel in patients with ...

Detalimogene voraplasmid gains FDA RMAT designation, showcasing a 71% response rate in treating high-risk, BCG-unresponsive ...

New study reveals mosunetuzumab and polatuzumab vedotin significantly improve outcomes for patients with relapsed large ...

Discover how data analytics transforms health care by reducing costs, improving patient outcomes, and enhancing operational ...

A panelist discusses how patients with advanced cGVHD often cycle through multiple approved agents over time due to ...